- Conditions
- Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Stage III Wilms Tumor
- Interventions
- laboratory biomarker analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Monrovia, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1441–1464
of 1,625
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Malignant Glioma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
- Interventions
- Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Samotolisib, X-Ray Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 125
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 96 more
- Conditions
- Xeroderma Pigmentosum, Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma, Skin Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Month to 99 Years
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Li-Fraumeni Syndrome, Neoplasms, Tp53 Mutations
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2012
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer
- Interventions
- DNA analysis, DNA methylation analysis, RNA analysis, gene expression analysis, polymerase chain reaction, diagnostic laboratory biomarker analysis, therapeutic conventional surgery
- Genetic · Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,045 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Interventions
- brentuximab vedotin, pembrolizumab
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 90
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 57 more
- Conditions
- Cancer
- Interventions
- KRAS-variant and microRNA binding site mutation testing
- Genetic
- Lead sponsor
- MiraKind
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2035
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pancreatic Cancer
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cryptococcosis
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome, PTEN Hamartoma Syndrome, Cowden Syndrome, Bannayan Syndrome, Bannayan Zonana Syndrome, Polyposis
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Liver Cancer, Hepatitis B, Hepatitis C, Hepatobiliary Cancers, Hepatobiliary Cancers Liver
- Interventions
- Not listed
- Lead sponsor
- Samuel So
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Melanoma
- Interventions
- Single agent, adjuvant anti-PD1 therapy
- Drug
- Lead sponsor
- John Kirkwood
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Urothelial Carcinoma
- Interventions
- Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily + atezolizumab 1200 mg, Derazantinib 200 mg twice daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily monotherapy (QD), Derazantinib 200 mg twice daily monotherapy
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Newnan, Georgia • New York, New York • Port Jefferson Station, New York + 4 more
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Cholangiocarcinoma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 4
- States / cities
- Bethesda, Maryland • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Epilepsy, Tuberous Sclerosis Complex, Focal Cortical Dysplasia
- Interventions
- Everolimus
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 2 Years to 40 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Benign Breast Condition, Breast Fibroadenoma, Breast Neoplasms, Breast Disease, Breast Cancer Female, Breast Pain, Breast Cancer Invasive, Breast Cancer Detection
- Interventions
- ATUSA 3D Automated Breast Ultrasound System
- Device
- Lead sponsor
- iSono Health, Inc.
- Industry
- Eligibility
- 18 Years to 94 Years · Female only
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Sacramento, California • Cypress, Texas
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
- Drug · Other
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Sacramento, California • Bonita Springs, Florida + 31 more
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Afatinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B
- Interventions
- Vandetanib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Solid Tumors
- Interventions
- PX-866
- Drug
- Lead sponsor
- Cascadian Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Houston, Texas
- Conditions
- Fanconi Anemia
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Fertility Issues
- Interventions
- Not listed
- Lead sponsor
- Bar-Chama, Natan, M.D.
- Other
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 75 participants
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cresskill, New Jersey
- Conditions
- Breast Cancer
- Interventions
- YouTube Video Arm
- Behavioral
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1
- Interventions
- Selumetinib, Sirolimus
- Drug
- Lead sponsor
- Sarcoma Alliance for Research through Collaboration
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 2 more